

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

NCT06909565

Status	RECRUITING
Phase	Phase 4
Sponsor	Duke University
Enrollment	6,000 participants

Key Eligibility Criteria

Inclusion (4)

- Signed informed consent must be obtained prior to participation in the study.
- Males or females e 18 years of age
- Within 14 days of a successful percutaneous coronary intervention (PCI) or peripheral endovascular intervention (PVI) for symptomatic CAD or lower extremity PAD
- Patients undergoing planned staged interventions are eligible for randomization only after the last planned intervention

Exclusion (8)

- Planned future PCI or PVI
- Current or planned use of an open-label PCSK9 inhibitor during the study
- Any prior treatment with inclisiran
- Active or planned participation in another clinical study involving investigational drugs or devices during the study
- Any serious liver disease, metabolic disease, neoplasm, end-stage kidney disease, or other condition in the opinion of the investigator that would inhibit trial participation or confound trial results
- ... and 3 more (see full listing online)

Locations (71 total)

Advanced Cardiovascular LLC, Alexander City, Alabama, United States
Heart Center Research, LLC, Huntsville, Alabama, United States
Arkansas Cardiology, Little Rock, Arkansas, United States
... and 68 more locations